DelveInsight’s “Homozygous Familial Hypercholesterolemia Pipeline Insight 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Homozygous Familial Hypercholesterolemia pipeline landscape. It covers the Homozygous Familial Hypercholesterolemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Homozygous Familial Hypercholesterolemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Homozygous Familial Hypercholesterolemia Pipeline? Click here to explore the therapies and trials making headlines @ Homozygous Familial Hypercholesterolemia Pipeline Outlook Report
Key Takeaways from the Homozygous Familial Hypercholesterolemia Pipeline Report
On 10 October 2025, Arrowhead Pharmaceuticals conducted a study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug during the OLE Period.
Want to know which companies are leading innovation in Homozygous Familial Hypercholesterolemia? Dive into the full pipeline insights @ Homozygous Familial Hypercholesterolemia Clinical Trials Assessment
The Homozygous Familial Hypercholesterolemia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Homozygous Familial Hypercholesterolemia Pipeline Report also highlights the unmet needs with respect to the Homozygous Familial Hypercholesterolemia.
Homozygous Familial Hypercholesterolemia Overview
Homozygous familial hypercholesterolaemia (HoFH) is a rare and life-threatening disease originally characterized clinically by plasma cholesterol levels >13 mmol/L (>500 mg/dL), extensive xanthomas, and marked premature and progressive atherosclerotic cardiovascular disease (ACVD). Studies in cultured fibroblasts from these patients showed a severe defect in the ability to bind and internalize LDL particles, subsequently shown to be caused by mutations in both alleles of the gene encoding the LDL receptor (LDLR). Recent genetic insights, however, indicate that mutations in alleles of other genes, including APOB, PCSK9, and LDLRAP1, may be present in some individuals with HoFH.
Homozygous Familial Hypercholesterolemia Emerging Drugs Profile
ARO-ANG3 is designed to reduce production of angiopoietin-like protein 3 (ANGPTL3), a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 inhibition has been shown to lower serum LDL, serum and liver triglyceride and has genetic validation as a novel target for cardiovascular disease. Currently, it is in Phase II stage of clinical trial evaluation to treat Homozygous Familial Hypercholesterolemia.
Tafolecimab injection, developed by Innovent, is an lgG2 fully human monoclonal antibody that can specifically bind to PCSK-9 and reduce LDL-C level by inhibiting PCSK-9-mediated low-density lipoprotein receptor (LDLR) endocytosis, subsequently enhancing the clearance of LDL-C, resulting in a reduction in LDL-C level.
If you’re tracking ongoing Homozygous Familial Hypercholesterolemia Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Homozygous Familial Hypercholesterolemia Treatment Drugs
The Homozygous Familial Hypercholesterolemia Pipeline report provides insights into:-
Homozygous Familial Hypercholesterolemia Companies
Arrowhead Pharmaceuticals, Innovent Biologics, Akeso Biopharma, LIB Therapeutics LLC and others.
Homozygous Familial Hypercholesterolemia Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
Homozygous Familial Hypercholesterolemia Products have been categorized under various Molecule types such as,
From emerging drug candidates to competitive intelligence, the Homozygous Familial Hypercholesterolemia Pipeline Report covers it all – check it out now @ Homozygous Familial Hypercholesterolemia Market Drivers and Barriers, and Future Perspectives
Scope of the Homozygous Familial Hypercholesterolemia Pipeline Report
Stay ahead in Healthcare Research – discover what’s next for the Homozygous Familial Hypercholesterolemia Treatment landscape in this detailed analysis @ Homozygous Familial Hypercholesterolemia Emerging Drugs and Major Players
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-pipeline-insight
